GlycoMimetics, Inc. To Present New Data on Lead Compounds at International Symposium; Proprietary Compound Significantly Reduces Inflammation in Animal Model.GAITHERSBURG, Md. -- GlycoMimetics, Inc. (GMI GMI Governance Metrics International (New York, New York) GMI Giant Magneto-Impedance GMI Global MSF Interoperability GMI General Motors Institute GMI General Mills, Inc. ), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced it will present new data from recent tests of its novel compounds at the annual International Symposium on Glycoconjugates next week in Italy. One of the anti-inflammatory compounds tested in animals showed "statistically significant and substantial inhibition" of inflammation, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. independent study investigators. GMI VP and Chief Scientific Officer John Magnani, Ph.D. will present the results in a lecture entitled "Rational Design of Small Molecule Glycomimetic Compounds that Bind Multiple Epitopes". An abstract of the session is available on the company's website, http://www.glycomimetics.com. Selected slides from the lecture, including data on the newest compound, will be available at the website following the meeting. "Our strategy was to design a molecule that targets multiple sites on cell surfaces that control the inflammatory response," says Magnani. "The increase in potency is dramatic. We can essentially shut down the inflammatory response in this animal model." "The results are an important validation of our strategy," adds GMI CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Rachel King. "We plan to develop our compounds into potential drug therapies for diseases in which inflammation plays a critical role. The early data is certainly encouraging." Dr. Magnani will also present information about a glycomimetic molecule designed by GMI that inhibits the functions of two different lectins Lectins A class of proteins of nonimmune origin that bind carbohydrates reversibly and noncovalently without inducing any change in the carbohydrate. Lectins bind a variety of cells having cell-surface glycoproteins (carbohydrate bound proteins) or glycolipids that are virulence factors produced by Pseudomonas aeruginosa Pseudomonas aeruginosa A normal soil inhabitant and human saprophyte that may contaminate various solutions in a hospital, causing opportunistic infection in weakened Pts Clinical Infective endocarditis in IVDAs, RTIs, UTIs, bacteremia, meningitis, 'malignant' . This bactertium is frequently associated with Cystic Fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , and causes ventilator ventilator /ven·ti·la·tor/ (ven´ti-la-tor) 1. an apparatus for qualifying the air breathed through it. 2. a device for giving artificial respiration or aiding in pulmonary ventilation. associated pneumonia and other infections. GMI plans to develop the compound to be used in conjunction with antibiotics to treat chronic or resistant infections. "These two projects in combination clearly demonstrate that glycomimetic molecules can be rationally designed to achieve biological activity," Magnani says. "The core chemistry is a platform for additional potential drug candidates." About GMI GlycoMimetics, Inc. ("GMI") is developing novel therapeutics based upon the roles that carbohydrates play in important biological processes. The Company believes that carbohydrate mimics ("glycomimetic" compounds) represent an important new class of therapeutics. GMI has raised a total of $9.6-million in a Series A round of venture financing. The company is using the funding for pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. of its lead compounds. More information is available at the company's web site: http://www.glycomimetics.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion